Sevasemten

DB18983InvestigationalSmall molecule

Sevasemten is under investigation in clinical trial NCT05291091 (Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)).

Chemical structure of Sevasemten
Formula / weight
C16H11F4N5O2 · 381.291 g/mol (avg)
Also known as
2-[(5-fluoropyridin-3-yl)methyl]-6-[2-(2,2,2- trifluoroethoxy)pyrimidin-5-yl]pyridazin-3(2H)-one
Code names
EDG-5506

Resolves to

Compound
UNIIJT5OYR0WUKCAS2417395-15-2
Structure
InChIKeyXFPJKQRXBAFXNK-UHFFFAOYSA-NSMILESFC1=CN=CC(CN2N=C(C=CC2=O)C2=CN=C(OCC(F)(F)F)N=C2)=C1

What you can answer from here — as of July 10, 2026

8Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Sevasemten, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In